Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: 225-actinium labelled-anti-carbonic anhydrase IX antibodies - Telix Pharmaceuticals/Nihon Medi Physics

Next Previous
Search
Drug Profile

Research programme: 225-actinium labelled-anti-carbonic anhydrase IX antibodies - Telix Pharmaceuticals/Nihon Medi Physics

Alternative Names: 225 labelled anti-CAIX antibodies - Telix Pharmaceuticals/Nihon Medi Physics; 225-actinium labelled girentuximab - Telix Pharmaceuticals/Nihon Medi Physics

Latest Information Update: 11 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nihon Medi-Physics; Telix Pharmaceuticals
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Renal cell carcinoma

Most Recent Events

  • 31 Mar 2025 Nihon Medi-Physics has been acquired by GE Healthcare
  • 28 Dec 2022 No recent reports of development identified for research development in Renal-cell-carcinoma in Japan (Parenteral)
  • 28 Dec 2022 No recent reports of development identified for research development in Renal-cell-carcinoma(Diagnosis) in Japan (Parenteral)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top